Pompe Disease Pipeline Insight 2024,with Comprehensive Insights for 15+ Companies and 20+ Pipeline Drugs in the Pompe Disease Pipeline Landscape
The "Pompe Disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The report provides comprehensive insights about 15+ companies and 20+ pipeline drugs ...
pharmaphorum2d
Beam points to positive data with key base editing asset
therapy for glycogen storage disease 1a. Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys ...
Nature2d
Gene therapy articles from across Nature Portfolio
In this mouse study, an adenine base editor shows potential as a durable therapy for glycogen storage disease type-Ia, correcting both the life-threatening lack of blood glucose control and ...
Health risks of uncontrolled blood sugar levels
Sugar in the blood is glucose. Insulin, a hormone produced by the pancreas, is the key that allows glucose to enter body ...
Hosted on MSN3d
Whole vs refined carbohydrates: What’s the difference?
Excess carbohydrates ingested get converted into glycogen in the liver and muscles of the body ... can help improve metabolism and also lower the risk of chronic diseases, and are good for muscle ...